Exelixis | EXEL - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 52.19M 2.62M 2025-12
Agios Pharmaceuticals USD 40.21M 4.31M 2025-12
Akebia Therapeutics USD 46.51M 7.82M 2025-03
Amgen USD 54.6B 17M 2025-12
AstraZeneca USD 33.92B 4.3B 2026-03
Bayer EUR 36.45B 2.93B 2025-12
BioMarin Pharmaceutical USD 1.44B 833.74M 2026-03
Bristol-Myers Squibb USD 47.14B 3.9B 2025-12
Cytokinetics USD 1.29B 4.48M 2026-03
Eisai JPY 236.67B 49.14B 2025-09
Eli Lilly USD 42.5B 3.6M 2025-12
Exelixis USD 169.54M 3.5M 2026-03
Genmab DKK 148M 5M 2025-06
Glaxosmithkline GBP 19.06B 1.31B 2026-03
Incyte USD 39.43M 982K 2026-03
Ionis Pharmaceuticals USD 2.34B 9.5M 2026-03
MacroGenics USD 36.51M 500K 2026-03
Merck USD 49.34B 7.97B 2025-12
Moderna USD 1.31B 571M 2025-12
Nektar Therapeutics USD 0 0 2022-06
Neurocrine Biosciences USD 406.2M 9.1M 2026-03
Novartis USD 47B 11.62B 2026-03
Pfizer USD 63.73B 231M 2026-03
Puma Biotechnology USD 89.06M 55.07M 2024-06
Sanofi EUR 20.02B 1.73B 2026-03
Takeda JPY 4.85T 208B 2025-12
Ultragenyx Pharmaceutical USD 36M 2.17M 2025-12
Xencor USD 187.75M 118.48M 2025-12